To evaluate feasibility and effectiveness of non-invasive VNS to enhance stroke recovery
In this study, (Aim 1) we will test whether our non-invasive trans-auricular vagus nerve stimulation (taVNS) during occupational therapy task performance has the potential for large scale application through superior clinical benefit compared to sham in a broad group of stroke survivors including hemorrhagic strokes. To determine the predictors of effective brain rewiring in the individual stroke patient, we will use an EEG and/or functional MRI (fMRI) connectivity biomarker independently of the success of the stimulation paradigm (Aim 2). We will test the hypothesis that better motor function will be associated with increased motor network connectivity pattern. The central objective of this application is to determine whether taVNS significantly improves motor recovery for both ischemic and hemorrhagic strokes through increased connectivity as measured by a biomarker of plasticity. We address our objective through the following aims: Aim 1: To determine the extent to which taVNS with concurrent occupational therapy (OT), causes significant, lasting motor gains in chronic stroke population Hypothesis A: More chronic stroke patients treated with taVNS+OT will show clinically meaningful improved hand motor function over Sham+OT immediately after treatment as measured by upper extremity Fugl-Meyer (uFM) test response rate. 60 patients at least 6 months after ischemic or hemorrhagic stroke with persistent arm weakness will be enrolled in a 6-week double masked, sham-controlled, balanced parallel group design phase 2 clinical trial. Hypothesis B: The sham group will achieve the same degree of motor function improvement in the open label cross-over phase as the original active taVNS group sustained clinical improvement after OT+VNS. Hypothesis C: The open label home extension taVNS+OT phase will produce additional motor function improvement and will be associated with improved patient and caregiver satisfaction. Aim 2: To determine the induced connectivity pattern of the brain resulting in the improved motor performance Hypothesis A: Chronic stroke patients with improved motor performance will demonstrate increased connectivity between motor cortical areas as measured by high-definition EEG and/or fMRI functional connectivity compared to the non-responders immediately after treatment. Hypothesis B: Network activation with taVNS is dependent on timing compared to movement and stimulation intensity. We will perform fMRI and /or high-definition EEG to evaluate network activity during taVNS at different intensity and phase of the movement. This study evaluates the feasibility, efficacy and underlying plasticity changes of adjuvant noninvasive VNS to enhance motor recovery following ischemic and hemorrhagic strokes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
60
Experimental. The current will be increased gradually for both sham and real stimulation at the beginning of the 90-minute stimulation to lessen the itchy/numb skin sensation and to create the same skin sensation for subject blinding.
Houston Methodist Research Institute
Houston, Texas, United States
RECRUITINGTo evaluate feasibility and effectiveness of non-invasive VNS to enhance stroke recovery
To determine the extent to which taVNS with concurrent occupational therapy (OT), causes significant, lasting motor gains in chronic stroke population Upper extremity Fugl-Meyer (uFM) The uFM test measures both proximal and distal upper extremity movements, ranges 0-66, higher score is better.
Time frame: [Time Frame: Baseline, post intervention (week 6), post intervention (week 12), and follow up for the sham crossover group (week 18)]
To evaluate the biomarkers of plasticity associated with VNS
We will use an EEG and/or functional MRI (fMRI) connectivity biomarker.
Time frame: [Time Frame: Baseline 1(week 1), post-intervention (week 6), post intervention for sham crossover only (week 12)]
Wolf Motor Function Test (WMFT)
The WMFT is a time-based method to evaluate upper extremity performance while providing insight into joint-specific and total limb movements. This measurement includes video recording of the task performance where de-identifying will be attempted to the degree possible (face not in the frame, removing/blocking out identifying jewelry etc.). All patients will sign an informed consent explicitly authorizing such video-recording.
Time frame: [Time Frame: Baseline, post intervention (week 6), post intervention (week 12), and follow up for the sham crossover group (week 18)]
Functional upper extremity levels (FUEL)
The FUEL is an upper extremity post-stroke motor function classification system that does not require significant extra time or evaluator training.
Time frame: [Time Frame: Baseline, post intervention (week 6), post intervention (week 12), and follow up for the sham crossover group (week 18)]
NIH STROKE SCALE (NIHSS)
The NIHSS is a standardized clinical examination to evaluate clinical functional impairment after stroke.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: [Time Frame: Baseline, post intervention (week 6), post intervention (week 12), and follow up for the sham crossover group (week 18)]. Max score 42, minimum score 0. Score of 0 is best outcome
MRC grading scale
The MRC grading scale is a clinical scale to evaluate the motor impairment.
Time frame: [Time Frame: Baseline, post intervention (week 6), post intervention (week 12), and follow up for the sham crossover group (week 18)]. Minimum score 0, max score 5 per item. 5 is normal, 0 is no movement.
Timed up and Go
This test assesses gait speed, mobility, balance, walking ability and fall risk in older adults.
Time frame: [Time Frame: Baseline, post intervention (week 6), post intervention (week 12), and follow up for the sham crossover group (week 18)]
Barthel Index (BI)
The Barthel Index is an index measuring the patients' activities of daily living and of patient's independence in mobility and personal care.
Time frame: [Time Frame: Baseline, post intervention (week 6), post intervention (week 12), and follow up for the sham crossover group (week 18)]. Minimum score 0, maximum score 100. Higher score is better
Stroke Impact Scale (SIS)
A self-report questionnaire that evaluates disability and health-related quality of life after stroke from the perspective of the patient.
Time frame: [Time Frame: Baseline, post intervention (week 6), post intervention (week 12), and follow up for the sham crossover group (week 18)]. Minimum score 0, maximum score 100. 0 means no recovery, 100 means fully recovered
Zarit Burden Interview: Short (12-items)
Caregiver perspective questionnaire to assess caregiver burden. Additional caregiver questionnaire for perception of user friendliness, time savings, helpfulness, ease of use, perceived improvement and free comments will be collected.
Time frame: [Time Frame: Baseline, post intervention (week 6), post intervention (week 12), and follow up for the sham crossover group (week 18)]
Modified Rankin Scale (mRS)
Clinician-reported measure of global disability that has been widely applied for evaluating recovery from stroke and as a primary end point in randomized clinical trials (RCTs) of emerging acute stroke treatments.
Time frame: [Time Frame: Baseline, post intervention (week 6), post intervention (week 12), and follow up for the sham crossover group (week 18)]
Modified Ashworth Spasticity Scale
The modified Ashworth spasticity scale provides a rating of the degree of spasticity of a limb evaluated by clinical neurologic examination.
Time frame: [Time Frame: Baseline, post intervention (week 6), post intervention (week 12), and follow up for the sham crossover group (week 18)]
Quick Inventory of Depressive Symptomatology, Self-report (QIDS-SR)
A validated 16-item0-27 scale self-report questionnaire of depression.
Time frame: [Time Frame: Baseline, post intervention (week 6), post intervention (week 12), and follow up for the sham crossover group (week 18)]. Minimum score 0, maximum score greater than 21. 0-5 means normal, greater than 21 is not
taVNS questionnaire
Visual Analog Scale to prospectively evaluate taVNS effects such as skin sensation, tingling, skin redness etc. This will serve as a safety and tolerability measure.
Time frame: [Time Frame: Baseline, post intervention (week 6), post intervention (week 12), and follow up for the sham crossover group (week 18)]
Motor Activity log
A structured interview to assess how stroke survivors use their affected arm outside of the laboratory.
Time frame: [Time Frame: Baseline, post intervention (week 6), post intervention (week 12), and follow up for the sham crossover group (week 18)]
Wrist flexion-extension measurement
This measurement will be performed with our hand device to record maximum force of flexion and extension in standard arm position. taVNS test improvement will be calculated based on the speed and accuracy of the writs flexion measurement as described in our prior published work.
Time frame: [Time Frame: Baseline, post intervention (week 6), post intervention (week 12), and follow up for the sham crossover group (week 18)]
To determine the taVNS induced connectivity pattern of the brain
Primary outcome measure: Hypothesis A and Hypothesis B: Connectivity measure between motor cortical areas as measured by high definition EEG and fMRI functional connectivity in taVNS compared to Sham+OT immediately after treatment
Time frame: [Time Frame: Baseline, post intervention (week 6), post intervention (week 12), and follow up for the sham crossover group (week 18)]